New York City is home to more than 1.1 million members of the Asian community. People of Asian descent are at increased risk for liver disease and have higher death rates from liver disease than any other racial group.
U.S. News & World Report’s “Best Hospitals” ranks NYU Langone among the top 10 hospitals in the country for gastroenterology and GI surgery.
This is why NYU Langone’s Asian Liver Health Program is dedicated to providing advanced, specialized care for people who have hepatitis B, hepatitis C, cirrhosis, liver cancer, and all other types of liver disease. Our team is sensitive to and knowledgeable about the unique and diverse needs of the Asian community.
NYU Langone’s Asian Liver Health Program provides New York City’s diverse Asian American community with the very best care in liver disease screening, diagnosis, and treatment, including liver transplantation. Our team of hepatologists (liver specialists), gastroenterologists, interventional radiologists, liver surgeons, medical oncologists, radiation oncologists, and liver transplantation experts works closely with our patients and their primary care physicians to ensure they receive the most advanced, integrated, and culturally sensitive care.
Our program also features multilingual staff, interpreter services, and educational materials in Asian languages.
The Asian Liver Health Program provides comprehensive care, including advanced medical care, interventional radiology procedures, and surgical options for people with liver disease.
For some patients with life-threatening liver disease, transplantation may offer the only hope for effective treatment and cure. Our team of highly skilled and experienced transplant hepatologists, surgeons, nurses, and other specialists works together before, during, and after the transplant procedure to ensure optimal outcomes for our patients and their families.
Patient survival rates at our state-of-the-art facility—NYU Langone's Transplant Institute—are consistently among the best in the nation.
At NYU Langone, we conduct pioneering clinical trials, ensuring that new, investigational therapies are available to our patients who have hepatitis, cirrhosis, liver cancer, and other types of liver disease.
530 First Avenue, HCC, Suite 4J, New York, NY, 10016